Day: March 22, 2022

InnoSIGN Completes Spin-Out from Philips with an $8M Series A Financing to Revolutionize Precision Medicine through its OncoSIGNal Pathway Activity Profiling Platform

InnoSIGN utilizes its proprietary database with over 100,000 pathway activity profiles for drug development and diagnostics to predict patient response...

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies...

error: Content is protected !!